Publication | Open Access

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

MedicineFnclcc/french Sarcoma GroupPathologyOncologyRadiation OncologyDesmoid TumorsCancer ResearchRecurrent Aggressive Fibromatosis